Cyclacel Pharmaceuticals Strengthens Its Partnership with FITTERS
Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP) has made a significant move to enhance its operational framework by amending its Exchange Agreement with FITTERS Diversified Berhad. This amendment signifies a strategic collaboration aimed at leveraging each company's strengths and expanding their market reach.
Details of the Exchange Agreement Amendment
Under the revised terms of the Exchange Agreement, all ordinary shares of FITTERS’ subsidiary, Fitters Sdn. Bhd., will be exchanged for common stock of Cyclacel, referred to as Purchaser Stock. Following this transaction, Fitters Sdn. Bhd. will become a wholly-owned subsidiary of Cyclacel. This transaction will include the issuance of Purchaser Stock that constitutes approximately 19.99% of the total issued shares as of the closing date.
Financial Considerations and Timeframe
As part of this transaction, Cyclacel will also provide a monetary consideration of USD $1,000,000 to FITTERS or another mutually agreed amount upon closing. The closing date has been extended, allowing all necessary approvals to be secured by September 30, 2025.
The Approval Process
For the Transaction to progress effectively, it must receive approval from stockholders of both Cyclacel and FITTERS. Notably, the boards of directors from both companies have shown unanimous support for this agreement.
About Fitters Sdn. Bhd.
Fitters Sdn. Bhd. is known for its expertise in fire safety materials and systems. With a strong reputation for reliability, they provide fire retardant uniforms, personal protective equipment, and various fire safety products ranging from extinguishers to fire-resistant doors. Their commitment to safety and quality serves a broad spectrum of sectors including commercial, industrial, healthcare, and residential needs.
Fitters' Mission and Offerings
The mission of Fitters is to deliver high-quality, certified safety solutions, ensuring compliance with regulatory standards. Their innovative approach has positioned them as a one-stop specialist in protective clothing and fire safety supplies, meeting diverse client demands.
About Cyclacel Pharmaceuticals, Inc.
Cyclacel is at the forefront of developing innovative cancer therapies that focus on cell cycle regulation, epigenetics, and mitosis biology. Among their active projects is the evaluation of plogosertib, a potent PLK1 inhibitor aimed at treating both solid tumors and hematological malignancies. The company concentrates on building a diverse pipeline of unique drug candidates targeting oncology and hematology.
Looking Ahead
This recent amendment reflects Cyclacel's commitment to enhancing its operational frameworks and diversifying its portfolio. By collaborating with FITTERS, Cyclacel is poised to harness new efficiencies and drive growth in the biopharmaceutical sector, ensuring that both companies benefit from shared resources and strategic synergies.
Frequently Asked Questions
What is the purpose of the amended Exchange Agreement between Cyclacel and FITTERS?
The amendment aims to strengthen the partnership by exchanging shares and establishing Fitters Sdn. Bhd. as a wholly-owned subsidiary of Cyclacel.
What percentage of Cyclacel's stock will FITTERS receive?
FITTERS will receive stock amounting to 19.99% of the total issued shares of Cyclacel as part of the transaction.
When is the expected closing date for the transaction?
The closing date has been extended to September 30, 2025, to allow time for necessary approvals.
What types of products does Fitters Sdn. Bhd. specialize in?
Fitters Sdn. Bhd. specializes in fire safety materials, including protective clothing, fire extinguishers, fire-resistant doors, and personal protective equipment.
What role does Cyclacel Pharmaceuticals play in cancer treatment?
Cyclacel focuses on developing innovative cancer therapies that target cell cycle regulation and mitosis biology to treat various forms of cancer.
